USFDA to review rules for infant formula production

The Food and Drug Administration will also consider whether to establish a dedicated group of investigators and realign staff across two of its divisions to better support regulatory oversight of infant formula, among other measures, it said.

The FDA's statement follows a major shortage of baby formula earlier this year due to a shutdown at Abbott's plant in Michigan after complaints of infection by a bacteria called cronobacter sakazakii.

Read also: Abbott recalls some Similac, other powder baby formulas due to Salmonella, Cronobacter complaints

The plant shutdown and the recall of Abbott infant formula products deepened a supply shortage and sent parents in the United States scrambling. Abbott's plant was restarted in July.

While bacterial infection is considered rare and is not reportable in most states, it can be deadly in newborns. Abbott's products were recalled following reports of four cases and two deaths.

Read also: Abbott recalls some ready-to-feed baby formula liquid products including Similac